Clinical Trials Logo

Clinical Trial Summary

The study will begin with an explanatory/training session where individuals with low vision will learn to use the V-NAV (Vortant NAVigation tool) indoor navigation app, and will have the opportunity to try it for a few representative tasks. The main activity includes a take-home trial, an extended unstructured period to emulate the post-purchase experience of users, during which participants will have the opportunity to use the V-NAV in their everyday lives. Data will be collected from the users to measure the relative advantage of V-NAV compared to the user's current indoor navigation method.


Clinical Trial Description

The introductory session, emphasizing real-world experiences, will involve a brief training session followed by simulated navigation experiences in a convenient location to the users. Participants will use V-NAV to record approximately 8 locations, then will be given instructions to find these locations again. The V-NAV prototype's logging software will measure distance walked and task time. Participants will complete a study-specific tool covering the relevant attributes of the V-NAV prototype, as well as a standardized tool, the NASA TLX (Task Load Index). Subsequently, participants will complete a take-home trial, during which they will be encouraged to use the V-NAV features regularly to support their everyday community navigation activities. Participants will be contacted approximately weekly with a "check-in" to answer questions and resolve any emergent technical problems. At the conclusion of the trial, a product-specific tool and an appropriate standardized tool, the PIADS (Psychosocial Impact of Assistive Devices Scale) will be administered. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05647694
Study type Interventional
Source Vortant Technologies, LLC
Contact
Status Suspended
Phase N/A
Start date June 1, 2024
Completion date September 30, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03841734 - Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO Phase 3
Completed NCT01942746 - Blueberry Effects on Dark Vision and Glare Recovery N/A
Completed NCT05608811 - The Effect of Social Skills Training in Visually Impaired Adolescents N/A